Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.40 |
| ▸ | WNT1 | P04628 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | SORD | Q00796 | 10/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509880 | 0.87 | HRH3 (0.41) | HRH4WNT1GSK3BDYRK1ASORD | |
| SCHEMBL510355 | 0.84 | HRH4 (0.49) | HRH4SORD | |
| SCHEMBL509702 | 0.83 | CXCR4 (0.45) | HRH4SORDTRPV1 | |
| SCHEMBL509308 | 0.83 | SORD (0.52) | HRH4WNT1GSK3BDYRK1AOGA | |
| SCHEMBL10212679 | 0.83 | SORD (0.40) | HRH4WNT1GSK3BDYRK1AOGA | |
| SCHEMBL509389 | 0.81 | PIK3CA (0.47) | OGA | |
| SCHEMBL509103 | 0.71 | WNT1 (0.37) | HRH4WNT1GSK3BDYRK1AOGA | |
| SCHEMBL510040 | 0.71 | WNT1 (0.37) | HRH4WNT1GSK3BDYRK1AOGA | |
| SCHEMBL10212801 | 0.69 | HRH3 (0.45) | WNT1GSK3BDYRK1ASORD | |
| SCHEMBL9205961 | 0.69 | KMT2A (0.64) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-8071605-B2 | Piperidine compounds for use in the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071605-B2 | Piperidine compounds for use in the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| WO-2010067123-A1 | 2- (PIPERIDIN-1-YL) -4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | TLR5, TLR2, PIR | HRH4 744/4885WNT1 4422/4885GSK3B 4208/4885 |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | NISCH, PAK6, MYD88 | HRH4 1025/4885WNT1 4110/4885GSK3B 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.